Antiplatelet therapy for secondary prevention of noncardioembolic ischemic stroke: A critical review

Stroke

Volumn 39, Issue 5, 2008, Pages 1638-1646

  O'Donnell, Martin J ^a,c   Hankey, Graeme J ^b   Eikelboom, John W ^a  

^a MCMASTER UNIVERSITY   (Canada)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c HAMILTON GENERAL HOSPITAL   (Canada)

Author keywords

Antiplatelet drugs; Aspirin; Clopidogrel; Therapy

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ACETYLSALICYLIC ACID PLUS DIPYRIDAMOLE; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; CILOSTAZOL; CLOPIDOGREL; DIPYRIDAMOLE; HEPARIN; LOTRAFIBAN; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; PLACEBO; SCH 530348; TERUTROBAN; THIENOPYRIDINE DERIVATIVE; THROMBIN INHIBITOR; THROMBOXANE SYNTHASE INHIBITOR; TICLOPIDINE; TRIFLUSAL; UNCLASSIFIED DRUG; WARFARIN;

ACUTE DISEASE; ANTICOAGULATION; ARTICLE; ASTHMA; BLEEDING; BRAIN HEMORRHAGE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CYTOPENIA; DIARRHEA; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG RELEASE; DRUG SAFETY; DRUG WITHDRAWAL; EXTRACRANIAL HEMORRHAGE; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; HEADACHE; HEART INFARCTION; HEART PALPITATION; HUMAN; LOADING DRUG DOSE; LONG TERM CARE; LOW DRUG DOSE; MONOTHERAPY; NEUTROPENIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; STROKE; TACHYCARDIA; THROMBOCYTOPENIA; THROMBOTIC THROMBOCYTOPENIC PURPURA; TRANSIENT ISCHEMIC ATTACK; TREATMENT OUTCOME; VASCULAR DISEASE; BRAIN ISCHEMIA; CHEMICALLY INDUCED DISORDER; DRUG COMBINATION; DRUG POTENTIATION; PATHOPHYSIOLOGY; REVIEW;

BRAIN ISCHEMIA; DRUG COMBINATIONS; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; HEMORRHAGE; HUMANS; PLATELET AGGREGATION INHIBITORS; RECURRENCE; STROKE; TREATMENT OUTCOME;

EID: 44449175655     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/STROKEAHA.107.497271     Document Type: Article

References (70)

1. Hankey GJ. Preventable stroke and stroke prevention. J Thromb Haemost. 2005;3:1638-1645.
2. Johnston SC, Gress DR, Browner WS, Sidney S. Short-term prognosis after emergency department diagnosis of TIA. JAMA. 2000;284: 2901-2906.
3. van WI, Kappelle LJ, van GJ, Koudstaal PJ, Franke CL, Vermeulen M, Gorter JW, Algra A. Long-term survival and vascular event risk after transient ischaemic attack or minor ischaemic stroke: a cohort study. Lancet. 2005;365:2098-2104.
4. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324:71-86.
5. Albers GW, Amarenco P, Easton JD, Sacco RL, Teal P. Antithrombotic and thrombolytic therapy for ischemic stroke. Chest. 2001;119: 300S-320S.
6. Deleted in proof.
7. The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. International Stroke Trial Collaborative Group. Lancet. 1997;349:1569-1581.
8. CAST (Chinese Acute Stroke Trial) Collaborative Group. CAST: randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. Lancet. 1997;349:1641-1649.
9. Roden-Jullig A, Britton M, Malmkvist K, Leijd B. Aspirin in the prevention of progressing stroke: a randomized controlled study. J Intern Med. 2003;254:584-590.
10. Multicentre Acute Stroke Trial-Italy (MAST-I) Group. Randomised controlled trial of streptokinase, aspirin, and combination of both in treatment of acute ischaemic stroke. Lancet. 1995;346:1509-1514.
11. Pince J. Thromboses veineuses des membres inferieurs et embolies pul-monaires au cours des accidents cerebreaux. A propos d'un essai comparatif de traitment preventif (These pour le doctorat d'etat en medicine). Toulouse: Universite Paul Sabatier, 1981.
12. Ciuffetti G, Aisa G, Mercuri M, Lombardini R, Paltriccia R, Neri C, Senin U. Effects of ticlopidine on the neurologic outcome and the hemorheologic pattern in the postacute phase of ischemic stroke: a pilot study. Angiology. 1990;41:505-511.
13. Utsumi H. Evaluation of utility of ticlopidine, an antiplatelet agent, for acute cerebral infarction. Guildford: Sanofi Winthrop (Sanofi internal report. 001.6.128) 1984. 2007.
14. Turpie AGG, Dobkin B, McKenna R. A trial of ticlopidine, an antiplatelet agent, for acute cerebral infarction. Guildford: Sanofi Winthrop (Sanofi internal report. 1983.001.6.188) 1983. 2007.
15. Ohtomo E, Kutsuzawa T, Kogure K, Hirai S, Goto F, Terashi Am, Tazaki Y, Araki G, Ito E, Fujishima M, Nakashima M. Clinical usefulness of OKY-046 on the acute stage of cerebral thrombosis - double blind trial in comparison with placebo. Rinsho Iyaku. (Journal of Clinical Therapeutics and Medicine) 1991;2007;7:353-388.
16. The Abciximab in Ischemic Stroke Investigators. Abciximab in acute ischemic stroke: a randomized, double-blind, placebo-controlled, dose-escalation study. Stroke. 2000;31:601- 609.
17. Adams HP Jr, Effron MB, Torner J, Davalos A, Frayne J, Teal P, Leclerc J, Oemar B, Padgett L, Barnathan ES, Hacke W; AbESTT-II investigators. Emergency administration of abciximab for treatment of patients with acute ischemic stroke: results of an international phase III trial: Abciximab in Emergency Treatment of Stroke Trial (AbESTT-II). Stroke. 2008;39:87-99.
18. Sandercock P, Gubitz G, Foley P, Counsell C. Antiplatelet therapy for acute ischaemic stroke. Cochrane Database Syst Rev. 2003;CD000029.
19. Deleted in proof.
20. Kennedy J, Hill MD, Ryckborst KJ, Eliasziw M, Denchuk AM, Buchan AM; FASTER Investigators. Fast assessment of stroke and transient ischaemic attack to prevent early recurrence (FASTER): a randomized controlled pilot trial. Lancet Neurol. 2007;6:961-969.
21. Berge E, Abdelnoor M, Nakstad PH, Sandset PM. Low molecular-weight heparin versus aspirin in patients with acute ischaemic stroke and atrial fibrillation: a double-blind randomised study. HAEST Study Group. Heparin in Acute Embolic Stroke Trial. Lancet. 2000;355:1205-1210.
22. Bath PM, Lindenstrom E, Boysen G, De DP, Friis P, Leys D, Marttila R, Olsson J, O'Neill D, Orgogozo J, Ringelstein B, van der SJ, Turpie AG. Tinzaparin in acute ischaemic stroke (TAIST): a randomised aspirin-controlled trial. Lancet. 2001;358:702-710.
23. Wong KS, Chen C, Ng PW, Tsoi TH, Li HL, Fong WC, Yeung J, Wong CK, Yip KK, Gao H, Wong HB. Low-molecular-weight heparin compared with aspirin for the treatment of acute ischaemic stroke in Asian patients with large artery occlusive disease: a randomised study. Lancet Neurol. 2007;6:407-413.
24. Berge E, Sandercock P. Anticoagulants versus antiplatelet agents for acute ischaemic stroke. Cochrane Database Syst Rev. 2002;CD003242.
25. Algra A, van GJ. Cumulative meta-analysis of aspirin efficacy after cerebral ischaemia of arterial origin. J Neurol Neurosurg Psych. 1999; 66:255.
26. Sorensen PS, Pedersen H, Marquardsen J, Petersson H, Heltberg A, Simonsen N, Munck O, Andersen LA. Acetylsalicylic acid in the prevention of stroke in patients with reversible cerebral ischemic attacks. A Danish cooperative study. Stroke. 1983;14:15-22.
27. The Canadian trial of aspirin and sulfinpyrazone in threatened stroke. N Engl J Med. 1978;299:953-955.
28. Swedish Aspirin Low-Dose Trial (SALT) of 75 mg aspirin as secondary prophylaxis after cerebrovascular ischaemic events. The SALT Collaborative Group. Lancet. 1991;338:1345-1349.
29. United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: interim results. UK-TIA Study Group. BMJ. (Clin Res Ed) 1988;296: 316-320.
30. Bousser MG, Eschwege E, Haguenau M, Lefaucconnier JM, Thibult N, Touboul D, Touboul PJ. "AICLA" controlled trial of aspirin and dipyr-idamole in the secondary prevention of athero-thrombotic cerebral ischemia. Stroke. 1983;14:5-14.
31. Fields WS, Lemak NA, Frankowski RF, Hardy RJ, Bigelow RH. Controlled trial of aspirin in cerebral ischemia. Circulation. 1980;62(6 Pt 2):V90-V96.
32. Diener HC, Cunha L, Forbes C, Sivenius J, Smets P, Lowenthal A. European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci. 1996;143:1-13.
33. Reuther RDW. Aspirin in patients with cerebral ischemia and normal angiograms or non-surgical lesions: the results of a double-blind trial. In Breddin K, Dorndorf W, Loew D, Marx R, eds. Acetylsalicyclic Acid in Cerebral Ischemia and Coronary Heart Disease. Stuttgart. Schattauer-Verlag, 1978:97-106.
34. Guiraud-Chaumeil B, Rascol A, David J, Boneu B, Clanet M, Bierme B. Prevention des recidives des accidents vasculaires cerebraux ischemiques par les anti-agregants plaquettaires: resultats d'un essai therapeutique controle de 3 ans. Rev Neurol. (Paris) 1982;138:367-385.
35. High-dose acetylsalicylic acid after cerebral infarction. A Swedish Cooperative Study. Stroke. 1987;18:325-334.
36. Boysen G, Sorensen PS, Juhler M, Andersen AR, Boas J, Olsen JS, Joensen P. Danish very-low-dose aspirin after carotid endarterectomy trial. Stroke. 1988;19:1211-1215.
37. McQuaid KR, Laine L. Systematic review and meta-analysis of adverse events of low-dose aspirin and clopidogrel in randomized controlled trials. Am J Med. 2006;119:624-638.
38. Campbell CL, Smyth S, Montalescot G, Steinhubl SR. Aspirin dose for the prevention of cardiovascular disease: a systematic review. JAMA. 2007;297:2018-2024.
39. Gent M, Blakely JA, Easton JD, Ellis DJ, Hachinski VC, Harbison JW, Panak E, Roberts RS, Sicurella J, Turpie AG. The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke. Lancet. 1989;1: 1215-1220.
40. Steinhubl SR, Tan WA, Foody JM, Topol EJ. Incidence and clinical course of thrombotic thrombocytopenic purpura due to ticlopidine following coronary stenting. EPISTENT Investigators. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting. JAMA. 1999;281:806-810.
41. Gotoh F, Tohgi H, Hirai S, Terashi A, Fukuuchi Y, Otomo E, Shinohara Y, Itoh E, Matsuda T, Sawada T, Yamaguchi T, Nishimaru K, Ohashi Y. Cilostazol Stroke Prevention Study: a placebo controlled double blind trial for secondary prevention of cerebral infarction. J Stroke Cerebrovasc Dis. 2000;9:147-157.
42. Hass WK, Easton JD, Adams HP Jr, Pryse-Phillips W, Molony BA, Anderson S, Kamm B. A randomized trial comparing ticlopidine hydro-chloride with aspirin for the prevention of stroke in high-risk patients. Ticlopidine Aspirin Stroke Study Group. N Engl J Med. 1989;321: 501-507.
43. Gorelick PB, Richardson D, Kelly M, Ruland S, Hung E, Harris Y, Kittner S, Leurgans S. Aspirin and ticlopidine for prevention of recurrent stroke in black patients: a randomized trial. JAMA. 2003;289:2947-2957.
44. Hankey GJ, Sudlow CL, Dunbabin DW. Thienopyridines or aspirin to prevent stroke and other serious vascular events in patients at high risk of vascular disease? A systematic review of the evidence from randomized trials. Stroke. 2000;31:1779-1784.
45. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet. 1996;348:1329-1339.
46. Culebras A, Rotta-Escalante R, Vila J, Dominguez R, Abiusi G, Famulari A, Rey R, Bauso-Tosselli L, Gori H, Ferrari J, Reich E. Triflusal vs aspirin for prevention of cerebral infarction: a randomized stroke study. Neurology. 2004;62:1073-1080.
47. Matias-Guiu J, Ferro JM, varez-Sabin J, Torres F, Jimenez MD, Lago A, Melo T. Comparison of triflusal and aspirin for prevention of vascular events in patients after cerebral infarction: the TACIP Study: a randomized, double-blind, multicenter trial. Stroke. 2003;34:840-848.
48. Matias-Guiu J, varez-Sabin J, Codina A. [Comparative study of the effect of low-dosage acetylsalicylic acid and triflusal in the prevention of cardiovascular events among young adults with ischemic cerebrovascular disease]. Rev Neurol. 1997;25:1669-1672.
49. Smirne S. Triflusal in the prevention of cerebrovascular attacks [Il tri-flusal nella prevenzione degli accidenti cerebrovasculari]. Giornale di Gerontologia. 1995;43:563-569.
50. Costa J, Ferro JM, Matias-Guiu J, varez-Sabin J, Torres F. Triflusal for preventing serious vascular events in people at high risk. Cochrane Database Syst Rev. 2005;CD004296.
51. Topol EJ, Easton D, Harrington RA, Amarenco P, Califf RM, Graf-fagnino C, Davis S, Diener HC, Ferguson J, Fitzgerald D, Granett J, Shuaib A, Koudstaal PJ, Theroux P, Van de WF, Sigmon K, Pieper K, Vallee M, Willerson JT. Randomized, double-blind, placebo-controlled, international trial of the oral IIb/IIIa antagonist lotrafiban in coronary and cerebrovascular disease. Circulation. 2003;108:399-406.
52. Bhatt DL, Fox KA, Hacke W, Berger PB, Black HR, Boden WE, Cacoub P, Cohen EA, Creager MA, Easton JD, Flather MD, Haffner SM, Hamm CW, Hankey GJ, Johnston SC, Mak KH, Mas JL, Montalescot G, Pearson TA, Steg PG, Steinhubl SR, Weber MA, Brennan DM, Fabry-Ribaudo L, Booth J, Topol EJ. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med. 2006;354: 1706-1717.
53. Bhatt DL, Flather MD, Hacke W, Berger PB, Black HR, Boden WE, Cacoub P, Cohen EA, Creager MA, Easton JD, Hamm CW, Hankey GJ, Johnston SC, Mak KH, Mas JL, Montalescot G, Pearson TA, Steg PG, Steinhubl SR, Weber MA, Fabry-Ribaudo L, Hu T, Topol EJ, Fox KA. Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J Am Coll Cardiol. 2007; 49:1982-1988.
54. Persantine Aspirin Trial in cerebral ischemia. Part II. Endpoint results. The Am-Canadian Co-Operative Study group. Stroke. 1985;16: 406-415.
55. Halkes PH, van GJ, Kappelle LJ, Koudstaal PJ, Algra A. Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial. Lancet. 2006;367: 1665-1673.
56. Kaye JA. A trial to evaluate the relative roles of dipyridamole and aspirin in the prevention of deep vein thrombosis in stroke patients. Bracknell. Boehringer Ingelheim (internal report): 1990.
57. De Schryver EL, Algra A, van GJ. Dipyridamole for preventing stroke and other vascular events in patients with vascular disease. Cochrane Database Syst Rev 2006;CD001820.
58. Diener HC, Bogousslavsky J, Brass LM, Cimminiello C, Csiba L, Kaste M, Leys D, Matias-Guiu J, Rupprecht HJ. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, doubleblind, placebo-controlled trial. Lancet. 2004;364:331-337.
59. Garde A, Samuelsson K, Fahlgren H, Hedberg E, Hjerne LG, Ostman J. Treatment after transient ischemic attacks: a comparison between anticoagulant drug and inhibition of platelet aggregation. Stroke. 1983;14: 677-681.
60. Olsson JE, Brechter C, Backlund H, Krook H, Muller R, Nitelius E, Olsson O, Tornberg A. Anticoagulant vs anti-platelet therapy as prophylactic against cerebral infarction in transient ischemic attacks. Stroke. 1980;11:4-9.
61. Algra A. Medium intensity oral anticoagulants versus aspirin after cerebral ischaemia of arterial origin (ESPRIT): a randomised controlled trial. Lancet Neurol. 2007;6:115-124.
62. The Stroke Prevention in Reversible Ischemia Trial (SPIRIT) Study Group. A randomized trial of anticoagulants versus aspirin after cerebral ischemia of presumed arterial origin. Ann Neurol. 1997;42:857-865.
63. Mohr JP, Thompson JL, Lazar RM, Levin B, Sacco RL, Furie KL, Kistler JP, Albers GW, Pettigrew LC, Adams HP Jr, Jackson CM, Pullicino P. A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. N Engl J Med. 2001;345:1444-1451.
64. Chimowitz MI, Lynn MJ, Howlett-Smith H, Stern BJ, Hertzberg VS, Frankel MR, Levine SR, Chaturvedi S, Kasner SE, Benesch CG, Sila CA, Jovin TG, Romano JG. Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis. N Engl J Med. 2005;352:1305-1316.
65. Stewart B, Shuaib A, eloso F. Stroke Prevention with Warfarin or Aspirin Trial (SWAT). Stroke. 1998;29:304 (Abst.P9).
66. Algra A, De Schryver EL, van GJ, Kappelle LJ, Koudstaal PJ. Oral anticoagulants versus antiplatelet therapy for preventing further vascular events after transient ischaemic attack or minor stroke of presumed arterial origin. Cochrane Database Syst Rev. 2006;3:CD001342.
67. Wardlaw JM, Zoppo G, Yamaguchi T, Berge E. Thrombolysis for acute ischaemic stroke. Cochrane Database Syst Rev. 2003;CD000213.
68. Mielke O, Wardlaw J, Liu M. Thrombolysis (different doses, routes of administration and agents) for acute ischaemic stroke. Cochrane Database Syst Rev. 2004;CD000514.
69. Yusuf S, Mehta SR, Zhao F, Gersh BJ, Commerford PJ, Blumenthal M, Budaj A, Wittlinger T, Fox KA. Early and late effects of clopidogrel in patients with acute coronary syndromes. Circulation. 2003107:966-972.
70. Diener HC, Sacco R, Yusuf S. Rationale, design and baseline data of a randomized, double-blind, controlled trial comparing two antithrombotic regimens (a fixed-dose combination of extended-release dipyridamole plus ASA with clopidogrel) and telmisartan versus placebo in patients with strokes: the Prevention Regimen for Effectively Avoiding Second Strokes Trial (PRoFESS). Cerebrovasc Dis. 2007;23:368-380.